Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism　― Insights From the J’xactly Study ―

Background: Rivaroxaban, a direct oral anticoagulant, is used as first-line treatment to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). However, the frequency of rivaroxaban discontinuation and the subsequent clinical outcomes remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Takeshi, Fukuda, Ikuo, Nakamura, Mashio, Yamada, Norikazu, Takayama, Morimasa, Maeda, Hideaki, Ikeda, Takanori, Mo, Makoto, Yamazaki, Tsutomu, Okumura, Yasuo, Hirayama, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2022
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360983/
https://www.ncbi.nlm.nih.gov/pubmed/36032386
http://dx.doi.org/10.1253/circrep.CR-22-0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360983/
https://www.ncbi.nlm.nih.gov/pubmed/36032386
http://dx.doi.org/10.1253/circrep.CR-22-0011

Ejemplares similares